Jul 9, 2026 04:01PM
Jun 18, 2026 08:00AM
Jun 18, 2026 08:00AM
May 21, 2026 06:00PM
May 21, 2026 06:00PM
May 7, 2026 04:01PM
Apr 6, 2026 05:55AM Denali regains full rights to brain therapy after Takeda ends partnership
Apr 3, 2026 01:30PM
Mar 26, 2026 08:35AM
Mar 25, 2026 04:02PM
Mar 25, 2026 01:05PM
Mar 25, 2026 12:38PM
Mar 25, 2026 11:50AM
Mar 25, 2026 11:50AM Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Mar 2, 2026 05:08PM
Feb 26, 2026 04:01PM
Feb 19, 2026 08:30AM
Feb 5, 2026 02:04PM
Feb 5, 2026 02:00PM
Jan 29, 2026 04:00PM
Jan 29, 2026 04:00PM Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
Jan 15, 2026 04:22AM
Jan 7, 2026 12:41AM
Jan 6, 2026 08:04AM
Jan 6, 2026 08:00AM
Dec 30, 2025 09:57AM
Dec 30, 2025 08:00AM
Dec 30, 2025 08:00AM The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Dec 5, 2025 07:32AM
Dec 4, 2025 07:10AM
Dec 4, 2025 07:02AM
Dec 4, 2025 07:00AM
Nov 6, 2025 04:01PM
Nov 6, 2025 04:00PM
Nov 6, 2025 04:00PM Denali Therapeutics Announces Board and Executive Leadership Updates
Oct 15, 2025 07:25AM
Oct 14, 2025 07:05AM
Oct 13, 2025 04:01PM
Oct 13, 2025 04:01PM
Aug 11, 2025 04:01PM
Jul 7, 2025 10:13AM
Jul 7, 2025 08:03AM FDA accepts Denali Therapeutics' (DNLI) hunter syndrome drug application
Jul 7, 2025 08:00AM
Jun 23, 2025 03:21PM
Jun 5, 2025 12:44PM
May 27, 2025 09:47AM
May 6, 2025 04:01PM
Apr 2, 2025 08:04AM
Apr 2, 2025 08:00AM Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126
Mar 7, 2025 08:12AM

325,464 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All